# US 12,215,159 B2 · Anti-CD161 antibodies and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,215,159 B2 - Document ID: US12215159B2 - Status: Granted - Kind: B2 - Application number: 18/582,950 - Filed: 2024-02-21 - Published: 2024-08-22 - Granted: 2025-02-04 - Earliest claimed: 2021-08-23 - Assignees: Immunitas Therapeutics, Inc. - Applicants: Immunitas Therapeutics, Inc. - Inventors: Alison Tisdale; Uli Bialucha; George Punkosdy; Alexandria Fusco; Frano Irvine; Emily Rosentrater; Elizabeth Scanlon; Michael Battles - Web page: https://patentgrep.com/patent/US12215159B2 ## CPC - C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72} - A61P 35/00: Antineoplastic agents - A61P 37/04: Immunostimulants - G01N 33/6854: {Immunoglobulins} - A61K 2039/505: {comprising antibodies} - C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity - C07K 2317/52: Constant or Fc region; Isotype - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention relates generally to anti-CD161 antibodies, pharmaceutical compositions comprising such antibodies, and methods of using such antibodies for treating disorders associated with or mediated by CD161, for example, certain cancers. In addition, the invention also relates to expression vectors and host cells for making these antibodies. ## Claims ### Claim 1 An isolated anti-CD161 antibody comprising: a heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 sequences, wherein: (a) the amino acid sequence of CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO: 72; (b) the amino acid sequence of CDR-H2 comprises the amino acid sequence set forth in SEQ ID NO: 73; (c) the amino acid sequence of CDR-H3 comprises the amino acid sequence set forth in SEQ ID NO: 74; and a light chain variable region comprising CDR-L1, CDR-L2 and CDR-L3 sequences, wherein: (d) the amino acid sequence of CDR-L1 comprises the amino acid sequence set forth in SEQ ID NO: 76; (e) the amino acid sequence of CDR-L2 comprises the amino acid sequence set forth in SEQ ID NO: 77; and (f) the amino acid sequence of CDR-L3 comprises the amino acid sequence set forth in SEQ ID NO: 78. ### Claim 2 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region comprises an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 71; and the amino acid sequence of the light chain variable region comprises an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 75. ### Claim 3 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 71; and the amino acid sequence of the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75. ### Claim 4 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the antibody is a full length antibody. ### Claim 5 (depends on 4) The isolated anti-CD161 antibody of claim 4, wherein the antibody is aglycosylated. ### Claim 6 (depends on 5) The isolated anti-CD161 antibody of claim 5, wherein the antibody comprises an IgG1 Fc region comprising a modification at amino acid position N297 according to EU numbering. ### Claim 7 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 71; and the amino acid sequence of the light chain variable region comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 75. ### Claim 8 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 71; and the amino acid sequence of the light chain variable region comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 75. ### Claim 9 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 71; and the amino acid sequence of the light chain variable region comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 75. ### Claim 10 (depends on 6) The isolated anti-CD161 antibody of claim 6, wherein the antibody comprises an alanine at amino acid position N297 according to EU numbering. ### Claim 11 (depends on 2) The isolated anti-CD161 antibody of claim 2, wherein the antibody is a full length antibody. ### Claim 12 (depends on 11) The isolated anti-CD161 antibody of claim 11, wherein the antibody is aglycosylated. ### Claim 13 (depends on 12) The isolated anti-CD161 antibody of claim 12, wherein the antibody comprises an IgG1 Fc region comprising a modification at amino acid position N297 according to EU numbering. ### Claim 14 (depends on 13) The isolated anti-CD161 antibody of claim 13, wherein the antibody comprises an alanine at amino acid position N297 according to EU numbering. ### Claim 15 (depends on 3) The isolated anti-CD161 antibody of claim 3, wherein the antibody is a full length antibody. ### Claim 16 (depends on 15) The isolated anti-CD161 antibody of claim 15, wherein the antibody is aglycosylated. ### Claim 17 (depends on 16) The isolated anti-CD161 antibody of claim 16, wherein the antibody comprises an IgG1 Fc region comprising a modification at amino acid position N297 according to EU numbering. ### Claim 18 (depends on 17) The isolated anti-CD161 antibody of claim 17, wherein the antibody comprises an alanine at amino acid position N297 according to EU numbering. ### Claim 19 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region comprises an amino acid sequence at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 71; and the amino acid sequence of the light chain variable region comprises an amino acid sequence at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 75. ### Claim 20 (depends on 19) The isolated anti-CD161 antibody of claim 19, wherein the antibody is a full length antibody. ### Claim 21 (depends on 20) The isolated anti-CD161 antibody of claim 20, wherein the antibody is aglycosylated. ### Claim 22 (depends on 21) The isolated anti-CD161 antibody of claim 21, wherein the antibody comprises an IgG1 Fc region comprising a modification at amino acid position N297 according to EU numbering. ### Claim 23 (depends on 22) The isolated anti-CD161 antibody of claim 22, wherein the antibody comprises an alanine at amino acid position N297 according to EU numbering. ### Claim 24 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region comprises an amino acid sequence at least 96% identical to the amino acid sequence set forth in SEQ ID NO: 71; and the amino acid sequence of the light chain variable region comprises an amino acid sequence at least 96% identical to the amino acid sequence set forth in SEQ ID NO: 75. ### Claim 25 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region comprises an amino acid sequence at least 97% identical to the amino acid sequence set forth in SEQ ID NO: 71; and the amino acid sequence of the light chain variable region comprises an amino acid sequence at least 97% identical to the amino acid sequence set forth in SEQ ID NO: 75. ### Claim 26 (depends on 1) The isolated anti-CD161 antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region comprises an amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO: 71; and the amino acid sequence of the light chain variable region comprises an amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO: 75. ### Claim 27 (depends on 26) The isolated anti-CD161 antibody of claim 26, wherein the antibody is a full length antibody. ### Claim 28 (depends on 27) The isolated anti-CD161 antibody of claim 27, wherein the antibody is aglycosylated. ### Claim 29 (depends on 28) The isolated anti-CD161 antibody of claim 28, wherein the antibody comprises an IgG1 Fc region comprising a modification at amino acid position N297 according to EU numbering. ### Claim 30 (depends on 29) The isolated anti-CD161 antibody of claim 29, wherein the antibody comprises an alanine at amino acid position N297 according to EU numbering.